HIF1A and neoplasm: A recent report from a group at MSKCC showed that a hypoxia-activated chemotherapeutic TH-302 combined with VEGF-A inhibition and RT, an exploratory tri-modality therapy, dramatically enhanced tumor response in preclinical models of sarcoma via increasing DNA damage and apoptosis in endothelial cells and decreasing HIF-1α activity [31].